Sanofi gets expanded meningitis vaccine approval

Apr 25, 2011

(AP) -- Sanofi Pasteur, the vaccines division of Sanofi-Aventis, said Monday the Food and Drug Administration approved the company's bacterial meningitis vaccine Menactra for children between the ages of 9 months and 23 months.

The disease is fairly rare in the United States, but those who get it develop symptoms quickly and can die in only a few days. Survivors can suffer mental disabilities, hearing loss and paralysis. The is spread by coughing, sneezing and kissing, and most cases occur in previously healthy children and young adults.

The company said this is the first U.S. approval for a bacterial for the age group between 9 months and 23 months.

Menactra was already approved for people ages 11 through 55 and children between 2 and 10 years old.

Explore further: Bristol-Myers: FDA blocks hepatitis C drug for now

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA expands meningitis vaccine approval

Oct 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

CDC panel: Teens need another meningitis shot

Oct 27, 2010

(AP) -- Teens should get a booster dose of the vaccine for bacterial meningitis because a single shot doesn't work as long as expected, a federal advisory panel said Wednesday.

ActHIB vaccine recalled in Japan

Mar 11, 2011

Sanofi Pasteur and Daiichi Sankyo on Friday announced a recall of the ActHIB vaccine in Japan after an "unidentified substance" was found in two syringes.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.